VacciXcell exhibited at the 9th Vaccine & ISV Congress held on 18-20th October at Lotte Hotel in Seoul, Korea. Products featured at the booth were the BelloCell® bioreactor system and the CelSafe® CO2 Incubator, which is an excellent combination for vaccine development.
The Vaccine & ISV Congress, which began in 2007, aimed to engage collaborations between different scientists and researchers in the hopes of the improving the vaccine development and manufacturing industry in the world. This year, the Vaccine & ISV Congress featured an excellent line up of speakers from across the globe and presented an array of topics, including clinical trials and field studies, animal models, immunology, and human vaccines against both infectious and non-infectious diseases.
VacciXcell founder, XL Lin, and members of the VacciXcell and Esco Korea Team were present at the event. They introduced the BelloCell® bioreactor, the CelSafe® CO2 Incubator, and the rest of the VacciXcell product line, which consists of upstream bioprocessing equipment all the way to filling line equipment. They also discussed the advantages of the use of VacciXcell's tide motion bioreactor in vaccine manufacturing.
The 9th Vaccine & ISV Congress was able to bring together brilliant minds to collaborate and discuss how to progress the vaccine development and manufacturing industry. In simpler words, it was a great a success. Thank you to all who visited our booth and we look forward to meeting you at our next event!
-min.png)
